Skip to content

Pulmonary Determinants of Cardiorespiratory Fitness in Fontan Patients

Pulmonary Determinants of Cardiorespiratory Fitness in Patients With Fontan Procedure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05684562
Enrollment
78
Registered
2023-01-13
Start date
2023-12-26
Completion date
2027-04-30
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Heart Disease, Fontan Procedure

Brief summary

This study will examine and record the patient's medical information and medical records (patient files, computer records, etc.). Physical examination, echocardiographic, electrocardiographic, laboratory, radiological, etc. evaluations are made during the routine controls of the patients. Within the scope of this study, no attempt will be made on the patients, no additional tests will be performed, or treatment changes will not be made in the patients because they are included in this study. After these records, KPET will be performed by a specialist doctor and physiotherapist for the patients who are directed to the Faculty of Physical Therapy and Rehabilitation Cardiopulmonary Rehabilitation Unit. Pulmonary function tests and respiratory muscle strength measurements will be performed on patients who have adequate rest after CPET.

Interventions

OTHERCardiopulmonary exercise test

CPET, the gold standard, will be used in the assessment of cardiorespiratory fitness. The cardiopulmonary exercise test system (Cosmed Quark CPET, Rome, Italy) is a safe method in which the patient can be monitored via ECG during the execution of the individual on a treadmill, and simultaneously lactate measurement, maximal O2 consumption, and CO2 production are evaluated. The Bruce protocol is the most commonly used method for KPET applied with a treadmill. However, since the Bruce protocol prefers high workload preferences, the Modified Bruce/half Bruce protocol with intermediate increments will be used. In addition, dyspnea, leg fatigue, and general fatigue at rest, during the test, and during the recovery phases after the test will be recorded with a sphygmomanometer using the Modified Borg Scale.

OTHERPulmonary function test

Pulmonary function testing will be performed with a spirometer (Cosmed Quark CPET, Rome, Italy) connected to the CPET system using standard procedures. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be saved.

Intraoral maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) will be used as indicators of respiratory muscle strength. A portable intraoral pressure gauge (MicroRPM, Micromedical, Kent, UK) and nose clip will be used during MIP and MEP assessments. MIP and MEP measurements will be obtained using standard procedures. 3 measurements will be made where the difference between each measurement is not more than 10% and the maximum value of MIP and MEP will be recorded.

Sponsors

Hacettepe University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
8 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

Fontan Group Inclusion Criteria: * Be between 8-55 years old * Having undergone a Fontan operation * Clinical stability of the patients (preserved ventricular function) * No change in ongoing drug therapy that adversely affects clinical stability * At least 1 year after the operation Fontan Group

Exclusion criteria

* Neurological and/or genetic musculoskeletal disease * Having orthopedic and cognitive problems that prevent testing * The patient's and/or family's unwillingness to participate in the study Control Group Inclusion Criteria: * Not have cardiovascular, neurological, and/or genetic musculoskeletal disease * Not having orthopedic and cognitive problems that prevent testing * The patient's and/or family's willingness to participate in the study

Design outcomes

Primary

MeasureTime frame
Maximal oxygen consumption30-45 minutes
Forced vital capacity (FVC)15-20 minutes
Forced expiratory volume in 1 second (FEV1)15-20 minutes
FEV1/FVC15-20 minutes
Maximal inspiratory pressure15-20 minutes
Maximal expiratory pressure15-20 minutes
Ratio curve of minute ventilation to carbon dioxide production (VE/VCO2) slope30-45 minutes
Ratio of minute ventilation to carbon dioxide production (VE/VCO2)30-45 minutes
Oxygen uptake efficiency slope (OUES)30-45 minutes
Minute ventilation (VE)30-45 minutes
End tidal oxygen pressure (PetO2)30-45 minutes
End tidal carbon dioxide pressure (PetCO2)30-45 minutes

Countries

Turkey (Türkiye)

Contacts

CONTACTHaluk Tekerlek
haluktekerlek@gmail.com+905355915009

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026